The FDA Modernization Act of 1997 established the Fast Track designation to expedite developing and reviewing new drugs designed to fill unmet medical needs and treat serious conditions. The FDA Fast ...
The U.S. Food and Drug Administration (FDA) has granted Johnson & Johnson’s, nipocalimab, Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results